FLK1 Signaling Protects Tumor Vasculature from Radiation

FLK1 信号传导保护肿瘤脉管系统免受辐射

• 批准号: 7025808
• 负责人: DENNIS E HALLAHAN
• 金额: $ 29.86万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7025808
• 关键词: athymic mouse; biological signal transduction; cytotoxicity; enzyme activity; free radical oxygen; ionizing radiation; kinase inhibitor; matrix assisted laser desorption ionization; neoplasm /cancer blood supply; neoplasm /cancer radiation therapy; phosphatidylinositol 3 kinase; phosphorylation; protein structure function; protein tyrosine kinase; protein tyrosine phosphatase; proteomics; radiation resistance; radiosensitizer; serine threonine protein kinase; tissue /cell culture; vascular endothelium

DESCRIPTION (provided by applicant): Tumor microvasculature is a therapeutic target in the treatment of cancer. The overall hypothesis of this translational research is that the cytotoxic effects of ionizing radiation on the tumor microvascular endothelium are attenuated by activation of the PI3K/Akt signaling pathway. We have found that ionizing radiation induces the activation of PI3K/Akt, which in turn regulates endothelial cell viability during treatment with radiotherapy. Inhibition of this signaling pathway enhances the cytotoxic effects of radiation in tumor vascular endothelium resulting in enhanced tumor control. The goals of the proposed research are to study the mechanisms by which ionizing radiation activates the PI3K/Akt signaling pathway. This research will lead to potential new molecular targets for therapy. Our overall goal is to bring this therapeutic strategy into clinical trials. We will, therefore, study inhibitors of this signal transduction pathway that are pipeline compounds for clinical trials. The proposed specific aims combine both basic and translational research with the intention of developing new strategies for the treatment of cancer. We hypothesize that radiation-induced activation of PI3K/Akt signaling in tumor microvasculature is initiated through 3 potential mechanisms: 1) ligand-mediated RTK activation; 2) direct RTK activation by radiation; and/or 3) inactivation of protein tyrosine phosphotases. These mechanisms are not mutually exclusive and may each contribute toward amplification of the PI3K/Akt signaling. In Specific Aim 1, we will determine the role of receptor tyrosine kinases in radiation-induced activation of the PI3K/Akt pathway. In Specific Aim 2, we will determine the role of protein tyrosine phosphotase (PTP) inactivation in radiation-induced activation of the PI3K/Akt signaling pathway. In Specific Aim 3, we will determine the biologically active dose of TKIs that enhance the cytotoxic effects of radiation on tumor vascular endothelium. We will identify molecular targets to improve local and regional control of cancers such as malignant gliomas and head and neck cancer. The importance of this study is that new molecular targets for radiation sensitization will be identified. Furthermore, we will characterize pipeline TKIs for clinical protocol development. The significance of this investigation is that quality of life; organ preservation and cure rates can be improved by enhancing the cytotoxic effects of localized irradiation through the use of tyrosine kinase inhibitors.

描述(申请人提供)：肿瘤微血管是癌症治疗的治疗靶点。这项翻译研究的总体假设是，电离辐射对肿瘤微血管内皮细胞的细胞毒作用通过激活PI3K/Akt信号通路而减弱。我们发现，电离辐射诱导PI3K/Akt激活，进而调节放射治疗过程中内皮细胞的活性。抑制这一信号通路可增强放射对肿瘤血管内皮细胞的细胞毒作用，从而增强肿瘤的控制力。本研究的目的是研究电离辐射激活PI3K/Akt信号通路的机制。这项研究将为治疗带来潜在的新分子靶点。我们的总体目标是将这一治疗策略应用于临床试验。因此，我们将研究这一信号转导途径的抑制剂，这些抑制剂是临床试验的流水线化合物。拟议的具体目标将基础研究和转化研究结合起来，意在开发治疗癌症的新策略。我们推测，辐射诱导肿瘤微血管中PI3K/Akt信号的激活是通过3种可能的机制启动的：1)配体介导的RTK激活；2)辐射直接激活RTK；和/或3)蛋白酪氨酸磷酸酶的失活。这些机制并不是相互排斥的，可能各自有助于PI3K/Akt信号的放大。 在特定的目标1中，我们将确定受体酪氨酸激酶在辐射诱导的PI3K/Akt通路激活中的作用。在特定的目标2中，我们将确定蛋白酪氨酸磷酸酶(PTP)失活在辐射诱导的PI3K/Akt信号通路激活中的作用。在具体目标3中，我们将确定TKIs的生物活性剂量，以增强辐射对肿瘤血管内皮细胞的细胞毒作用。我们将确定分子靶点，以改善对恶性胶质瘤和头颈癌等癌症的局部和区域控制。这项研究的重要性是将识别用于辐射增敏的新的分子靶标。此外，我们将为临床方案开发确定流水线TKI的特征。这项研究的意义在于，通过使用酪氨酸激酶抑制剂来增强局部照射的细胞毒性效应，可以提高生活质量、器官保存和治愈率。